| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from the issuance of secured long-term credit facility | 125,000 | - |
| Fees associated with the issuance of secured long-term credit facility | 8,400 | - |
| Payment on finance leases | 300 | 200 |
| Net cash provided by (used in) financing activities | 72,400 | 16,200 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | 700 | 700 |
| Change in cash and cash equivalents classified as held for sale | - | 0 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 42,900 | -28,200 |
| Cash and cash equivalents at beginning of period | 111,900 | - |
| Cash and cash equivalents at end of period | 154,800 | - |
MYRIAD GENETICS INC (MYGN)
MYRIAD GENETICS INC (MYGN)